Skip to main content
Sreyashi Basu on Muck Rack

Sreyashi Basu

As seen in: Nature, Frontiers, Science Magazine, BioRxiv, Cell Press, Cancer Discovery, Texas Medical Center
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sreyashi

Contact Sreyashi, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial

|
By Padmanee Sharma, Michael Krainer, Fred Saad, Daniel Castellano, Jens Bedke, Mariusz Kwiatkowski, Akash Patnaik, Giuseppe Procopio, Christian Thomas, Steven McCune, Steinbjørn Hansen, Gedske Daugaard, Sumit K. Subudhi, Sreyashi Basu, Sonali Jindal, Bilal Siddiqui, Ana Lako, Saurabh Gupta Verified, Neha Amin, Yumeng Wang, Justin David, Russell K. Pachynski, Paweł Wiechno, Samith Kochuparambil, Craig Kukard, Viktor Fedorov, Arancha Campos
| Nature Verified
Abstract We report on the randomized portion of the phase 2, open-label CheckMate 650 trial (NCT02985957), in which docetaxel-experienced, biologically male patients with chemotherapy-refractory metastatic castration-resistant prostate cancer were randomized 2:2:1:2 to nivolumab 3 mg /kg plus ipilimumab 1 mg /kg (n = 73), nivolumab 1 mg /kg plus ipilimumab 3 mg /kg (n = 74), ipilimumab 3 mg /kg (n = 38), or cabazitaxel (n = 74).
Open in Who Shared Issue with article?

Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses

|
By Alexander Ling, Jennifer Gantchev, Michael C. Prabhu, Sreyashi Basu
| Science Magazine Verified
Editor’s summary A major challenge with evaluating therapy responses to glioblastoma (GBM) is that longitudinal readouts are thought to be limited to clinical imaging with magnetic resonance imaging (MRI). Here, Ling et al. challenged the idea that serial sampling of GBM is not feasible. The authors report longitudinal tumor biopsy collection and multiomic readouts for two patients participating in a clinical trial of the oncolytic HSV CAN-3110.
Open in Who Shared Issue with article?

Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy - Nature

|
By Erez N. Baruch, Frederico O. Gleber-Netto, Priyadharsini Nagarajan, michael davies, Sonali Jindal, Sreyashi Basu, Ali Ahmadi, Derrick L. Tao, Nadim J. Ajami, Andrew Futreal, Kunal Rai, Sharia Hernandez, Jing L. Wang, Stephanie S. Watowich, George A. Calin, Mona M Yuan, Naijiang Liu, William L Hwang, Paola D. Vermeer, Nisha J. D’Silva, Yuri L. Bunimovich, Jared K. Burks, Javier Gomez, Javier Gómez, Patrick Dougherty, Kenneth Y. Tsai, Padmanee Sharma, Jennifer Wargo, Jeffrey Myers, Sebastien Talbot, Neil Gross
| Nature Verified
Abstract Perineural invasion (PNI) is a well-established factor of poor prognosis in multiple cancer types1, yet its mechanism remains unclear. Here we provide clinical and mechanistic insights into the role of PNI and cancer-induced nerve injury (CINI) in resistance to anti-PD-1 therapy. Our study demonstrates that PNI and CINI of tumour-associated nerves are associated with poor response to anti-PD-1 therapy among patients with cutaneous squamous cell carcinoma, melanoma and gastric cancer.
Open in Who Shared Issue with article?
See all 16 articles